

Supporting Information for

TLR agonists delivered by plant virus and bacteriophage nanoparticles for cancer immunotherapy

Eunkyeong Jung¹, Young Hun Chung^{2,3}, Nicole F Steinmetz^{1,2,3,4,5,6,}*

¹Department of NanoEngineering, University of California, San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

²Department of Bioengineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA

³Moore's Cancer Center, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.

⁴Center for Nano-ImmunoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.

⁵Department of Radiology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.

⁶Institute for Materials Discovery and Design, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.

Email: nsteinmetz@ucsd.edu

KEYWORDS drug delivery platforms, cowpea mosaic virus, cowpea chlorotic mottle virus, bacteriophage Q β , TLR7 agonist, TLR3 agonist, cancer immunotherapy




Figure S1. Characterization of native CPMV, CCMV and Q β particles. (A) Representative TEM image of CPMV, CCMV and Q β particles. Scale bar = 200 nm. (B) SEC profiles of CPMV, CCMV and Q β particles.




Figure S2. Comparative *in vivo* therapeutic efficacy of native CPMV, CCMV and Q β particles in (A) B16F10 and (B) CT26 murine cancer models. Arrows indicate the treatment days.




Figure S3. Characterization of Cy5-labeled CPMV, CCMV and Qβ particles. (A) Schematic diagram showing the synthesis method. (B) Agarose gel electrophoresis. (C) SEC profiles.




Figure S4. Biodistribution of Cy5-labeled CPMV, CCMV and Q β particles. We administered Cy5-labeled particles i.d. (100 μ g/20 μ L) and monitored fluorescence for 7 days. Yellow dotted lines indicate PBS-treated control mice.




Figure S5. Characterization of CPMV-poly(I:C) particles. (A) Schematic diagram showing the synthesis method. MeIm – 1-methylimidazole; EDC – 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. (B) TEM image of CPMV-poly(I:C) particles. Scale bar = 200 nm. (C) Size distribution and (D) surface charge of CPMV and CPMV-poly(I:C) particles dispersed in 0.1 M KP buffer. The boxed inset shows the average diameter (D, nm) and polydispersity (PDI) of the particles. (E) Agarose gel electrophoresis of CPMV, CPMV-poly(I:C) and poly(I:C). Left panel shows UV light exposure and right panel shows gel stained with Coomassie Brilliant Blue followed by white light exposure. (F) SEC profile of CPMV-poly(I:C). The boxed insets show the elution volume (V, mL) and the absorbance ratio at 260 and 280 nm (A260/280).




Figure S6. Evaluation of NF- κ B/AP-1 activation in RAW-Blue cells by CPMV-poly(I:C).
 Data are means \pm SEM (n = 6). The results were compared by one-way ANOVA with Tukey's multiple comparisons test (**P < 0.001, *P < 0.05).